Spectral Medical
Market Cap
CA$85.2m
Last Updated
2020/11/26 23:01 UTC
Data Sources
Company Financials +
Executive Summary
Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Spectral Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EDT is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EDT's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
1.4%
EDT
4.9%
CA Biotechs
2.8%
CA Market
1 Year Return
-42.2%
EDT
80.8%
CA Biotechs
-0.3%
CA Market
Return vs Industry: EDT underperformed the Canadian Biotechs industry which returned 76.8% over the past year.
Return vs Market: EDT underperformed the Canadian Market which returned -0.5% over the past year.
Shareholder returns
| EDT | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.4% | 4.9% | 2.8% |
| 30 Day | -7.5% | 24.7% | 10.0% |
| 90 Day | -28.8% | 25.8% | 5.7% |
| 1 Year | -42.2%-42.2% | 80.8%80.8% | 3.3%-0.3% |
| 3 Year | 12.1%12.1% | 18.5%18.5% | 12.2%1.3% |
| 5 Year | -54.9%-54.9% | 6.0%6.0% | 49.1%26.2% |
Long-Term Price Volatility Vs. Market
How volatile is Spectral Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Companies Like Spectral Medical (TSE:EDT) Are In A Position To Invest In Growth1 month ago | Simply Wall St
Does Spectral Medical's (TSE:EDT) CEO Salary Compare Well With Industry Peers?2 months ago | Simply Wall St
A Look At The Intrinsic Value Of Spectral Medical Inc. (TSE:EDT)Valuation
Is Spectral Medical undervalued compared to its fair value and its price relative to the market?
64.75x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EDT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EDT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EDT is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: EDT is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EDT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EDT is overvalued based on its PB Ratio (64.8x) compared to the CA Biotechs industry average (6.2x).
Next Steps
Future Growth
How is Spectral Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
10.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EDT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EDT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EDT's revenue (126% per year) is forecast to grow faster than the Canadian market (6.1% per year).
High Growth Revenue: EDT's revenue (126% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Spectral Medical performed over the past 5 years?
17.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDT is currently unprofitable.
Growing Profit Margin: EDT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDT is unprofitable, but has reduced losses over the past 5 years at a rate of 17.3% per year.
Accelerating Growth: Unable to compare EDT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).
Return on Equity
High ROE: EDT has a negative Return on Equity (-618.71%), as it is currently unprofitable.
Next Steps
Financial Health
How is Spectral Medical's financial position?
Financial Position Analysis
Short Term Liabilities: EDT's short term assets (CA$8.7M) exceed its short term liabilities (CA$2.5M).
Long Term Liabilities: EDT's short term assets (CA$8.7M) exceed its long term liabilities (CA$6.1M).
Debt to Equity History and Analysis
Debt Level: EDT is debt free.
Reducing Debt: EDT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EDT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 35.9% each year
Next Steps
Dividend
What is Spectral Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.8yrs
Average management tenure
CEO
Paul Walker (71 yo)
19.58yrs
Tenure
CA$789,840
Compensation
Dr. Paul M. Walker, MD, PhD, FRCS, has been the Chief Executive Officer and President of Spectral Medical Inc. since April 2001. Dr. Walker serves as the Chief Executive Officer and President of Sepsis, In...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD606.80K) is above average for companies of similar size in the Canadian market ($USD166.12K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 19.58yrs | CA$789.84k | 0.79% CA$ 671.1k | |
| CFO & COO | 1.25yrs | CA$391.02k | 0.048% CA$ 40.8k | |
| President of Dialco Medical Inc. | no data | CA$293.42k | 0.11% CA$ 91.7k | |
| Vice President of Clinical Development | 9.75yrs | CA$267.28k | 0.069% CA$ 58.4k |
9.8yrs
Average Tenure
Experienced Management: EDT's management team is seasoned and experienced (9.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 19.58yrs | CA$789.84k | 0.79% CA$ 671.1k | |
| Independent Director | 10.67yrs | CA$76.91k | 1.51% CA$ 1.3m | |
| Independent Chairman of the Board | no data | CA$114.68k | 0.24% CA$ 207.0k | |
| Independent Director | 0.25yr | no data | no data | |
| Independent Director | 6.17yrs | CA$74.66k | 0.16% CA$ 139.8k | |
| Independent Director | 2.5yrs | no data | no data |
6.2yrs
Average Tenure
Experienced Board: EDT's board of directors are considered experienced (6.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EDT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.
Top Shareholders
Company Information
Spectral Medical Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Spectral Medical Inc.
- Ticker: EDT
- Exchange: TSX
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$85.178m
- Shares outstanding: 236.61m
- Website: https://www.spectraldx.com
Number of Employees
Location
- Spectral Medical Inc.
- 135 The West Mall
- Unit 2
- Toronto
- Ontario
- M9C 1C2
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EDT | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Jul 1992 |
| EDTX.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Jul 1992 |
| SD4 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jul 1992 |
Biography
Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/26 23:01 |
| End of Day Share Price | 2020/11/26 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.